Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Anpac Bio surpasses...

    Anpac Bio surpasses 50,000 case study milestone Liquid Biopsy Pioneer serving individual, medical, insurance and corporate customers

    Written by Ruby Khatun Khatun Published On 2017-10-23T09:00:59+05:30  |  Updated On 18 Aug 2021 3:16 PM IST

    SACRAMENTO, California: Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.


    Described as "game-changing", and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection.


    By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing and generating results within minutes of sample submission.


    Comprehensive research validity data from the 50,000+ cases processed to date demonstrate CDA diagnostics consistently detect over 26+ cancers -- with a sensitivity and specificity rate range of 75%-90% -- usually identifying the disease at its earliest stages.


    The company has filed over 200 CDA-related patent applications worldwide – 65+ issued currently; and maintains operations in six sites, employing over 100 people globally.


    "Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia's most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. And as this research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand. We're now processing CDA tests for individuals, health systems, insurance companies, educational institutions, and corporations. We're very proud that our CDA devices have advanced beyond the laboratory, and are processing real tests for real people – saving lives every day. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"

    50American Society of Clinical OncologyAnpac BioAnpac Bio-Medical Science CompanyCancer Differentiation Analysiscase studycorporate customersDr Chris YuinsuranceLiquid Biopsy Pioneermedicalmilestoneserving individualsurpasses
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok